Physician profile
Jacob A Beans
NPI 1457894347
$4,185.83
in general payments reported to CMS, 2019-2025
26 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.23 · 2022: $360 · 2023: $1,044 · 2024: $1,318 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,795.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,063.38 | 2022-2025 | Breztri, Fasenra, Tezspire |
| Genzyme Corporation | $692.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $589.11 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $302.50 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $210.00 | 2023-2025 | Wakix |
| Grifols USA, LLC | $202.15 | 2022-2025 | Prolastin-C Liquid |
| Philips North America LLC | $139.21 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Inspire Medical Systems, INC. | $123.32 | 2023-2024 | Inspire |
| Insmed, INC. | $119.69 | 2024-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $83.33 | 2023-2024 | Winrevair, Capvaxive, Vaxneuvance |
| Mylan Specialty L.P. | $83.11 | 2023-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $73.96 | 2024-2025 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.65 | 2024-2025 | Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $61.77 | 2023-2025 | |
| Inogen, INC. | $61.25 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $52.09 | 2025 | Lumryz |
| Lilly USA, LLC | $46.37 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $30.28 | 2023 | Sunosi |
| Gilead Sciences, INC. | $26.42 | 2024 | |
| Jazz Pharmaceuticals INC. | $26.03 | 2025 | |
| 3b Medical, INC. | $25.59 | 2024 | Luna |
| Electromed, INC. | $23.11 | 2024 | Smartvest |
| Pfizer INC. | $21.37 | 2024 | |
| Resmed Corp | $19.31 | 2023 | |
| Baxter Healthcare | $18.45 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Scpharmaceuticals INC. | $17.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Beans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.